<DOC>
	<DOCNO>NCT02990858</DOCNO>
	<brief_summary>This extension study , provide continued access PRO 140 subject complete participation PRO140_CD02 continue receive clinical benefit would require PRO 140 form viable regimen , opinion treat physician . The patient population trial treatment-experienced HIV infect patient CCR5-tropic virus demonstrate evidence HIV-1 suppression successfully complete 24 week treatment PRO140_CD02 study .</brief_summary>
	<brief_title>An Extension Protocol Subjects Who Successfully Completed PRO140_CD02 Study</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>Potential subject require meet follow criterion enrollment study . 1 . Subjects complete 24 week treatment PRO 140_CD 02 study , Investigator believe subject require continued access PRO 140 order continue derive clinical benefit maintain HIV1 viral suppression 2 . HIV1 RNA â‰¤ 50 copies/ml T23 Visit PRO140_CD02 study 3 . Both male female patient partner childbearing potential must agree use 2 medically accept method contraception ( e.g. , barrier contraceptive [ male condom , female condom , diaphragm spermicidal gel ] , hormonal contraceptive [ implant , injectables , combination oral contraceptive , transdermal patch , contraceptive ring ] , intrauterine device ) course study ( exclude woman childbearing potential men sterilize ) . Females childbearing potential must negative urine pregnancy test prior receive first dose study drug . 4 . Willing able participate aspect study , include use SC medication , completion subjective evaluation , attendance schedule clinic visit , compliance protocol requirement evidence provide write informed consent . Potential subject meet follow criterion exclude enrollment . 1 . Not currently enrol PRO 140_CD 02 study 2 . Any active infection malignancy require acute therapy ( exception local cutaneous Kaposi 's sarcoma ) 3 . Females pregnant , lactating , breastfeeding , plan become pregnant study 4 . Any clinical condition , Investigator 's judgment , would potentially compromise study compliance ability evaluate safety measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>